Its sale to Allergan was called off at the last minute. One year later, a biotech co-founded by Henri Termeer finds a new buyer
Lysosomal Therapeutics went into JP Morgan 2017 with a sale all but sealed. With $100 million upfront and a $48 million cash infusion to execute …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
